119 related articles for article (PubMed ID: 36155707)
1. Effects of direct anti-viral agents on the gut microbiota in patients with chronic hepatitis C.
Huang PY; Chen CH; Tsai MJ; Yao CC; Wang HM; Kuo YH; Chang KC; Hung CH; Chuah SK; Tsai MC
J Formos Med Assoc; 2023 Feb; 122(2):157-163. PubMed ID: 36155707
[TBL] [Abstract][Full Text] [Related]
2. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis.
Wellhöner F; Döscher N; Woelfl F; Vital M; Plumeier I; Kahl S; Potthoff A; Manns MP; Pieper DH; Cornberg M; Wedemeyer H; Heidrich B
Hepatology; 2021 Jul; 74(1):72-82. PubMed ID: 33411981
[TBL] [Abstract][Full Text] [Related]
3. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
[TBL] [Abstract][Full Text] [Related]
4. Changes in the gut microbiota after hepatitis C virus eradication.
Honda T; Ishigami M; Yamamoto K; Takeyama T; Ito T; Ishizu Y; Kuzuya T; Nakamura M; Kawashima H; Miyahara R; Ishikawa T; Hirooka Y; Fujishiro M
Sci Rep; 2021 Dec; 11(1):23568. PubMed ID: 34876650
[TBL] [Abstract][Full Text] [Related]
5. Gut Dysbiosis Associated With Hepatitis C Virus Infection.
Inoue T; Nakayama J; Moriya K; Kawaratani H; Momoda R; Ito K; Iio E; Nojiri S; Fujiwara K; Yoneda M; Yoshiji H; Tanaka Y
Clin Infect Dis; 2018 Aug; 67(6):869-877. PubMed ID: 29718124
[TBL] [Abstract][Full Text] [Related]
6. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
Cacciola I; Russo G; Filomia R; Pitrone C; Caccamo G; Giandalia A; Alibrandi A; Stella Franzè M; Porcari S; Maimone S; Saitta C; Squadrito G; Raimondo G
Liver Int; 2021 Sep; 41(9):2059-2067. PubMed ID: 33894103
[TBL] [Abstract][Full Text] [Related]
7. Microbiota and hepatitis C virus in the era of direct-acting antiviral agents.
Pinchera B; Moriello NS; Buonomo AR; Zappulo E; Viceconte G; Villari R; Gentile I
Microb Pathog; 2023 Feb; 175():105968. PubMed ID: 36626945
[TBL] [Abstract][Full Text] [Related]
8. Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection.
Chuaypen N; Jinato T; Avihingsanon A; Chirapongsathorn S; Cheevadhanarak S; Nookaew I; Tanaka Y; Tangkijvanich P
J Infect Dis; 2021 Oct; 224(8):1410-1421. PubMed ID: 33598686
[TBL] [Abstract][Full Text] [Related]
9. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
[TBL] [Abstract][Full Text] [Related]
10. Non-selective dampening of the host immune response after hepatitis C clearance and its association with circulating chemokine and endotoxin levels.
Quinn G; Ali RO; Zhang GY; Hill K; Townsend E; Umarova R; Chakraborty M; Ahmad MF; Gewirtz M; Haddad J; Rosenzweig S; Rampertaap S; Schoenfeld M; Yang S; Koh C; Levy E; Kleiner DE; Etzion O; Heller T
Liver Int; 2023 Dec; 43(12):2701-2712. PubMed ID: 37752797
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients.
Wu SF; Tseng CW; Ho YC; Chen YC; Ko PH; He YT; Tseng KC
Dig Dis Sci; 2020 May; 65(5):1385-1395. PubMed ID: 31559553
[TBL] [Abstract][Full Text] [Related]
12. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
[TBL] [Abstract][Full Text] [Related]
13. Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents.
Hsu YC; Chen CC; Lee WH; Chang CY; Lee FJ; Tseng CH; Chen TH; Ho HJ; Lin JT; Wu CY
Sci Rep; 2022 Mar; 12(1):5481. PubMed ID: 35361930
[TBL] [Abstract][Full Text] [Related]
14. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
Lin CP; Liang PC; Huang CI; Yeh ML; Hsu PY; Hsu CT; Wei YJ; Liu TW; Hsieh MY; Hou NJ; Jang TY; Lin YH; Wang CW; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
PLoS One; 2021; 16(2):e0245479. PubMed ID: 33539408
[TBL] [Abstract][Full Text] [Related]
15. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
17. Reverse inflammaging: Long-term effects of HCV cure on biological age.
Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
[TBL] [Abstract][Full Text] [Related]
18. Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with hepatitis C virus.
Endo K; Sato T; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
Nutrition; 2022 Sep; 101():111699. PubMed ID: 35700590
[TBL] [Abstract][Full Text] [Related]
19. Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia.
Satoh T; Uojima H; Wada N; Takiguchi H; Kaneko M; Nakamura M; Gonda N; Homma M; Hidaka H; Kusano C; Horie R
Platelets; 2023 Dec; 34(1):2161498. PubMed ID: 36597279
[TBL] [Abstract][Full Text] [Related]
20. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients.
Pérez-Matute P; Íñiguez M; Villanueva-Millán MJ; Recio-Fernández E; Vázquez AM; Sánchez SC; Morano LE; Oteo JA
Eur J Intern Med; 2019 Sep; 67():47-58. PubMed ID: 31221551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
